Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 73 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Sicca Syndrome Clear all

Conditions: Keratoconjunctivitis Sicca
Interventions: Omega-3 Fatty Acid, Soybean Soft Gels; Dietary Supplement
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Keratoconjunctivitis Sicca, Dry Eye Disease
Interventions: Lifitegrast, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 13
States / cities: Waterbury, Connecticut • Louisville, Kentucky • Augusta, Maine + 10 more

Conditions: Keratoconjunctivitis Sicca
Interventions: cyclosporine, vehicle of OTX-101; Drug
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 18 Years and older
Enrollment: 745 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 3
States / cities: Rancho Cordova, California • Edgewood, Kentucky • New York, New York

Conditions: Keratoconjunctivitis Sicca, Xeropthalmia
Interventions: Acupuncture, Sham acupuncture; Procedure
Lead sponsor: Walter Reed Army Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Keratoconjunctivitis Sicca, Sjogren's Syndrome, Lupus Erythematosus, Systemic, Arthritis, Rheumatoid, Scleroderma, Systemic
Interventions: Ophthalmic Emulsion; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 17
States / cities: La Jolla, California • Los Angeles, California • Waterbury, Connecticut + 14 more

Conditions: Keratoconjunctivitis Sicca, Dry Eye Syndrome
Interventions: Dexamethasone, Artificial tear; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Keratoconjunctivitis Sicca
Interventions: Low Dose 0.155µg/mL SkQ1 ophthalmic solution, High Dose 1.55µg/mL SkQ1 ophthalmic solution, Placebo (Vehicle) opthalmic solution; Drug
Lead sponsor: Mitotech, SA; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Keratoconjunctivitis Sicca
Interventions: Systane Ocular Drops (OTC), Placebo - Saline Drops; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 88 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Ocular Inflammation, Keratoconjunctivitis, Dry Eye Disease (DED), Post-operative Complications, Kerato Conjunctivitis Sicca, Dry Eye Syndromes, Postoperative Complications
Interventions: Fluorometholone Acetate Ophthalmic Suspension 0.1%, Loteprednol Etabonate Ophthalmic Gel 0.38%; Drug
Lead sponsor: Harrow Inc; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Keratoconjunctivitis Sicca, Dry Eye
Interventions: rebamipide 2% ophthalmic suspension, placebo eye drops; Drug
Lead sponsor: Kubota Vision Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 19
States / cities: Mesa, Arizona • Phoenix, Arizona • Los Angeles, California + 14 more

Conditions: Kerato Conjunctivitis Sicca
Interventions: KPI-121 Ophthalmic Suspension, Vehicle; Drug
Lead sponsor: Kala Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 901 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 81
States / cities: Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 64 more

Conditions: Keratoconjunctivitis Sicca
Interventions: Retaine™; Drug
Lead sponsor: Ocusoft, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions: rebamipide 2% ophthalmic suspension, placebo eye drops; Drug
Lead sponsor: Kubota Vision Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 5
States / cities: Waterbury, Connecticut • Louisville, Kentucky • Lewiston, Maine + 2 more

Conditions: Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions: Omega-3 EFA Supplement, Olive Oil; Drug
Lead sponsor: Asbell, Penny, M.D.; Individual
Eligibility: 18 Years to 90 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Keratoconjunctivitis Sicca, Dry Eye Disease
Interventions: OTX-101 0.05%, OTX-101 0.09%, Vehicle; Drug
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 18 Years and older
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Dry Eye Disease
Interventions: INV-102, Vehicle; Drug
Lead sponsor: Invirsa, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Rush, New York

Conditions: Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions: KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension; Drug
Lead sponsor: Kala Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 909 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 62
States / cities: Birmingham, Alabama • Chandler, Arizona • Jonesboro, Arkansas + 54 more

Conditions: Chronic Graft-versus-host Disease
Interventions: R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%, Placebo Ophthalmic Solution; Drug · Other
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Plantation, Florida • Boston, Massachusetts

Conditions: Dry Eye Syndrome, Keratoconjunctivitis Sicca
Interventions: Oculeve Intranasal Neurostimulator; Device
Lead sponsor: Oculeve, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 2
States / cities: Artesia, California • Newport Beach, California

Conditions: Healthy, Sicca Syndrome, Sjögren's Syndrome
Interventions: Biopsy; Procedure
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Hartford, Connecticut • Boston, Massachusetts • Philadelphia, Pennsylvania + 1 more

Conditions: Dry Eye Disease
Interventions: INV-102, Vehicle; Drug
Lead sponsor: Invirsa, Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Rush, New York

Conditions: Dry Eye
Interventions: RU-101; Biological
Lead sponsor: R-Tech Ueno, Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Dry Eye Disease, Kerato Conjunctivitis Sicca
Interventions: Pilocarpine Ophthalmic Topical Cream, Dose 1, Pilocarpine Ophthalmic Topical Cream, Dose 2, Pilocarpine Ophthalmic Topical Cream, Dose 3, Placebo Ophthalmic Topical Cream; Drug
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 19
States / cities: Chandler, Arizona • Sun City, Arizona • Glendale, California + 16 more

Conditions: Sjögren´s Disease
Interventions: VAY736, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 23
States / cities: Peoria, Arizona • Searcy, Arkansas • Van Nuys, California + 20 more

Search by objective public record fields.

Omega-3 Fatty Acid Supplements and Dry Eye

Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)

Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Acupuncture Treatment of Dry Eye

Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome

Effects of Dry Eye Treatments on the Ocular Surface

A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)

Effects of Systane Versus Saline in Maintaining Tear Film Stability at Determined Time Points

Tolerability Comparison of Flarex to Lotemax SM

Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea

Safety and Efficacy of KPI-121 in Subjects With DED

A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome

Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye

Dry Eye Assessment and Management: Feasibility Study

Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease

Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease

Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)

Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator

A Longitudinal, Observational Biomarker Study in Participants With Primary Sjogren's Syndrome

Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease

A Phase 1/2, RU-101 Ophthalmic Solution in Patients With Severe Dry Eye

Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease

Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden